1Litman T,Druley TE,Stein WO,et al.From MDR to MXR:new understanding of multidrug resistance systems,their properties and clinical significance.Cell Mol Life Sci,2001,58:931-959.
2Tan B,Piwnica-worms D,Ratner L.Multidrug resistance transporters and modulation.Curr Opin Oncol,2000,12(5):450-458.
3Naito S,Kotoh S,Omoto T,et al.Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer:a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone.Cancer Chemother Pharmacol,1998,42(5):367-372.
4Duffy PM,Hayes MC,Cooper A,et al.Determination and reversal of resistance to epirubicin intravesical chemotherapy,a flow cytometric model.Br J Urol,1996,77(6):819-823.
5Leith C.Multidrug resistance in leukemia.Curr Opin Hematol,1998,5:287-291.
6Fukushima T,Yamashita T.Effect of PSC833 on the cytotoxicity and pharmacodynamics of mitoxantrone in multidrug resistance K562 cells.Leuk Res,2000,24(3):249-354.
7Hideki E,Takenari G.Reversal of P-Glycoprotein mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line.Cancer Res,2002,93:1037-1046.
8Mistry P,Stewart A,Dangerfield W,et al.In vitro and vivo reversal of P-Glycoprotein mediated multidrug resistance by a novel potent modulator,XR9576.Cancer Res,2001,61:749-758.
9Hastic ND,Held WA.Analysis of mRNA populations by cDNA-mRNA hybrid-mediated inhibition of cell-free protein synthesis.Proc Natl Acad Sci USA,1978,75:1217-1221.
10Clark RE.Antisense therapeutics in chronic myeloid leukemia:the promise,the progress and the problems.Leukemia,2000,14(3):347-355.
